Two Chinese pharmaceutical companies ranked among the top 25 global pharmaceutical brand value companies for the first time!

Guide: this year, the most valuable brands in the pharmaceutical industry have been expanded to 25 for the first time Sinopharm and Shanghai Pharmaceutical (SPH) have become the only two selected pharmaceutical brands in China Including Takeda, there are three pharmaceutical companies in Asia that have entered the global ranking Recently, brand finance, a British brand value consulting company, released "ranking of top 25 global brand value pharmaceutical companies in 2020" (brand finance Pharma 25 2020 ranking) No 1 Johnson & Johnson, with brand value down 11% to $10.9 billion from 2019, is still the most valuable brand in the pharmaceutical industry Roche, the second with a brand value of US $7.6 billion, has a big gap with Novartis, a competitor in the same country Bayer, third, lost 17 per cent to $5.1 billion in brand value as the acquisition of Monsanto damaged its brand image Pfizer is the pharmaceutical company with the fastest decline in brand value in 2020, down 20% to $3.8 billion This year, the most valuable brands in the pharmaceutical industry expanded to 25 for the first time, with Sinopharm and Shanghai Pharmaceutical (SPH) becoming the only two selected brands in China Including Takeda, there are three pharmaceutical companies in Asia that have entered the global ranking Top 10 brand value details of top 25 global pharmaceutical brands in 2020 top 5 brand value trends in the past seven years 2019-2020 brand value change range (%) most valuable pharmaceutical brands in the country photo source: brand finance Johnson & Johnson Johnson & Johnson has a relatively strong performance in the research and development of antibacterial drugs, with 25 projects, and this research and development field has attracted more and more global attention because it has not been occupied by competitors Johnson & Johnson failed to meet its financial target in the last quarter of 2019, which resulted in a 11% drop in brand value, but it is still far ahead Richard Haigh, managing director of brand finance, said: "Johnson & Johnson tops the list because of its continuous investment in R & D Recently, the novel coronavirus vaccine has been launched Through timely and relevant R & D plans, Johnson & Johnson is expected to maintain its leading position in the industry in the next few years " Over the years, the gap between the brand value of Roche and Novartis, Switzerland's two major pharmaceutical competitors, has been widening Roche has benefited from cancer drug development and the expanding Chinese market; Novartis has been hampered by unprofitable investment in Alcon After three years of brand value growth, Bayer's acquisition of Monsanto has had a disastrous impact on its reputation The market value of Bayer's brand is not equal to the total consideration for the acquisition of Monsanto But the company's recent acquisition of bluerock therapeutics has put it back on track, marking the company's focus on the pharmaceutical industry and the restart of stagnant drug production lines Pfizer's earnings have fallen sharply as a result of poor performance (up 7% to $3.5bn) in its consumer health products business with GSK But Pfizer merged its patent expired brand with Upjohn, the generic business unit, and mylan, the generic drug company The combined brand is viatris In the long run, this new start may bring higher brand value After Asia expands the list of the most valuable pharmaceutical brands in the world in 2020, Asian brands appear in the list for the first time The brand value of Sinopharm group and Takeda is about 2 billion US dollars With the rapid development of China's medical equipment industry, Sinopharm Holdings has taken the opportunity to expand its business in the industry and acquired 60% shares of China Science Equipment Co., Ltd After that, Takeda quickly reshaped its brand after acquiring shire, increasing Takeda's exposure in the world's largest pharmaceutical market (the United States), and adding the valuable pharmaceutical portfolio of shire to its product line Currently, Takeda is listed on both the Tokyo and New York stock exchanges, expanding its global business by entering larger capital markets and extending trading hours for global investors Reference: 1 Johnson & Johnson takes Pharma brand crown as Pfizer's value falls: ranking https:// 2 Brand finance Pharma 25 2020 Https://brandirectorypublic.s3.eu-west-2.amazon aws.com/reports_free / brand finance pharma-25-2020-preview.pdf 3.johnson & Johnson in health lead as world's most valuable Pharma brand https://brandfinance.com/news/press-releases/johnson-and-johnson-in-health-lead-as-worlds-most-valuable-pharma-brand/editor in charge Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.